The CRABP1 Knockout Raji Polyclonal Cells represent a polyclonal population of Raji B lymphocytes engineered via CRISPR/Cas9-mediated gene disruption to eliminate expression of cellular retinoic acid binding protein 1 (CRABP1). This knockout model provides a valuable system for dissecting the cytosolic sequestration and metabolic channeling of retinoic acid, enabling researchers to probe how loss of CRABP1 impacts nuclear receptor signaling and downstream cellular processes in a B-cell lymphoma background. The polyclonal nature encompasses heterogeneous editing events, delivering a robust loss-of-function platform while avoiding the selective pressures associated with clonal isolation.
The Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma B lymphocyte model extensively characterized for studies of humoral immunity, antigen presentation, and lymphomagenesis. Originating from a Burkitt lymphoma patient, these cells retain germinal center B cell features and display sensitivity to retinoic acid-induced differentiation and growth modulation. This oncogenic background, marked by constitutive NF-??B activity and MYC dysregulation, provides a clinically pertinent setting for exploring the interplay between retinoid signaling and B-cell transformation, particularly in the context of apoptosis resistance.
CRABP1 functions as a high-affinity cytosolic binder of all-trans retinoic acid, sequestering the ligand away from nuclear receptors RAR?? and RXR, thereby attenuating RAR/RXR-driven transcription. It also facilitates retinoic acid catabolism via interaction with CYP26A1. The CRABP1-CRABP2 shuttle establishes a rheostat controlling genomic responses, with downstream targets including CYP26A1, HOX genes, and apoptosis regulators. Through these mechanisms, CRABP1 modulates cell proliferation and differentiation, acting as a key node in retinoid homeostasis.
In the Raji lymphoma model, ablation of CRABP1 is anticipated to raise free intracellular retinoic acid levels, thereby potentiating RAR/RXR-mediated transcription and unmasking retinoid-dependent antiproliferative and pro-apoptotic programs. This functional alteration offers a unique opportunity to investigate how the CRABP1-CRABP2 shuttle modulates the balance between survival and death signals in EBV-positive B cells, and to evaluate the contribution of retinoic acid metabolism to Burkitt lymphoma pathogenesis and therapeutic sensitivity.
Applications include RARE-luciferase reporter assays to quantify retinoic acid transcriptional activity, RNA-seq for transcriptome-wide responses to retinoids, flow cytometry for apoptosis or B cell markers, Western blotting, RT-qPCR, and drug sensitivity profiling to identify retinoid-related vulnerabilities. The cells support functional genomics screens and mechanistic studies of retinoid sensitivity in Burkitt lymphoma and other B-cell malignancies. For further information or to discuss experimental design, please contact Ascent Research.
